Tunable Elastomers with an Antithrombotic Component for Cardiovascular Applications

This study reports the development of a novel family of biodegradable polyurethanes for use as tissue engineered cardiovascular scaffolds or blood‐contacting medical devices. Covalent incorporation of the antiplatelet agent dipyridamole into biodegradable polycaprolactone‐based polyurethanes yields biocompatible materials with improved thromboresistance and tunable mechanical strength and elasticity. Altering the ratio of the dipyridamole to the diisocyanate linking unit and the polycaprolactone macromer enables control over both the drug content and the polymer cross‐link density. Covalent cross‐linking in the materials achieves significant elasticity and a tunable range of elastic moduli similar to that of native cardiovascular tissues. Interestingly, the cross‐link density of the polyurethanes is inversely related to the elastic modulus, an effect attributed to decreasing crystallinity in the more cross‐linked polymers. In vitro characterization shows that the antiplatelet agent is homogeneously distributed in the materials and is released slowly throughout the polymer degradation process. The drug‐containing polyurethanes support endothelial cell and vascular smooth muscle cell proliferation, while demonstrating reduced levels of platelet adhesion and activation, supporting their candidacy as promising substrates for cardiovascular tissue engineering. A family of biodegradable polyurethanes is developed with an antiplatelet drug incorporated directly into the polymer backbone for use in blood‐contacting biomedical constructs. Adjusting the degree of cross‐linking in the polyurethane networks enables the polymer mechanical properties to be tuned, yielding strong materials with elasticity that better matches that of native cardiovascular tissues.